Day: April 10, 2023

Boston, April 10, 2023 (GLOBE NEWSWIRE) — Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, is honored to be ranked a Dominant Provider in Aite-Novarica’s P/C Policy Administration Systems Impact Report, indicating strong market position and momentum. Aite-Novarica is a leading analyst research firm and provides this report to assist P&C insurers in drawing up their short lists of potential providers based on vendor market position and offering details. The 2023 P/C Policy Administration Systems Impact Report provides an overview of the key features and capabilities, client base, lines of business supported, strategic partnerships, key differentiators, and product roadmaps of core standalone technology solutions providers. This report...

MINNEAPOLIS, April 10, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs today announced that an abstract about CPP-1X (also known as DFMO or Eflornithine) research, has been accepted for poster presentation at the Immunology of Diabetes Society (IDS) meeting, which will be held May 23-27, 2023. The research is part of a multi-site clinical trial led by Indiana University School of Medicine, supported by funding from JDRF, the leading global type 1 diabetes research and advocacy organization. Panbela Therapeutics is providing the drug at no cost to researchers. Details of the presentation are as follows: Poster PresentationTitle: Inhibition of Polyamine Biosynthesis with...

Naples, Florida, April 10, 2023 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC:SONG) is excited to share its latest findings on artificial intelligence (AI) applications in the music industry. After an extensive review of OpenAI documentation and numerous university papers, our Chief Technology Officer, Rodrigo Di Federico, has identified significant opportunities for innovation in the field of AI-generated music. While current AI systems like OpenAI’s ChatGPT have shown promise in various applications, experienced musicians often find it challenging to extract valuable melody, rhythm, and other musical elements from these models. Recognizing the potential of AI in revolutionizing the music industry, Music Licensing, Inc. (OTC:SONG) aims to develop a proprietary AI music system that addresses these limitations. By building...

Net Asset Value Anticipated to be $7.35 to $7.85 Per Share Tender Offer Expiring on April 17, 2023 at 5:00 P.M. Eastern Time NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) — SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) today provided the following preliminary update on its investment portfolio for the first quarter ended March 31, 2023. Additionally, the Company reminded its stockholders its modified “Dutch Auction” tender offer, which commenced on March 21, 2023, remains scheduled to expire at 5:00 P.M., Eastern Time, on April 17, 2023. “The challenging task of predicting the path of the economy, inflation, and changes in Federal Reserve policy, combined with the recent stress in the banking sector, have led to continued volatility and confusion in the public equity markets. With over $124.0...

FREMONT, CA, April 10, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Phase 1 Site Initiation Visit (SIV) of ABV-1601 was successfully conducted at Cedars-Sinai Medical Center (CSMC) in West Hollywood, California on March 31, 2023. The SIV was an organized meeting to discuss Phase I study protocol with the principal investigator, Scott A. Irwin, M.D., Ph.D. and begin training clinical personnel. ABV-1601, the Phase I open-label study will be conducted with 12 cancer patients with moderate to severe depressive symptoms. The main objective of the study is to evaluate the safety of PDC-1421, the primary active ingredient in ABV-1601, in cancer patients. “We...

VANCOUVER, British Columbia, April 10, 2023 (GLOBE NEWSWIRE) — FIREWEED METALS CORP. (“Fireweed” or the “Company”) (TSXV: FWZ; OTCQB: FWEDF, formerly Fireweed Zinc Ltd.) is pleased to announce that it has retained PI Financial Corp. (“PI”) to provide market-making services in accordance with TSX Venture Exchange Policies. PI will trade the securities of Fireweed on the TSXV for the purpose of maintaining an orderly market. In consideration of the services provided by PI, the Company will pay PI a monthly fee of $4,000 for a minimum term of three months and renewable thereafter. Fireweed and PI are unrelated and unaffiliated entities. PI will not receive shares or options as compensation. The capital used for market-making will be provided by PI. About Fireweed Metals Corp. (TSXV: FWZ; OTCQB: FWEDF; FSE:20F): Fireweed Metals is...

BOTHELL, Wash., April 10, 2023 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common stock at a price of $1.97 per share for proceeds of $4.0 million. Investors in the private placement were Cocrystal Director and co-founder Phillip Frost, M.D., who serves as Chairman and CEO of OPKO Health, and Fred Hassan who is Chairman of the investment firm Caret Group and Director of the private equity firm Warburg Pincus. Mr. Hassan also is a board member of Precigen, Prometheus Biosciences and BridgeBio and formerly served as Chairman and CEO of Schering-Plough Corporation and Chairman of Bausch and Lomb. Dr. Frost and Mr. Hassan each invested $2.0 million. “This investment by two highly accomplished, active industry leaders is a...

LUXEMBOURG, April 10, 2023 (GLOBE NEWSWIRE) — Arrival, (Nasdaq: ARVL) (“Arrival” or the “Company”), held an extraordinary general meeting of shareholders (“EGM”) on April 6, 2023, and shareholders approved all of the resolutions proposed by the Arrival board of directors. Among other resolutions, the EGM approved a share consolidation of all the shares of the Company by means of a reverse stock split at a consolidation ratio of 1-for-50 (the “Consolidation Ratio”) as subsequently determined by the board of directors of the Company. All resolutions set out in the convening notice published on March 16 and updated on March 30, 2023 were duly passed, including approval of:Reduction in the share capital of the Company by an amount of USD 83,525,590.13 so as to reduce it from its current amount of USD 83,682,122.35 to USD 156,532.22...

SoundThinking’s new SafetySmart platform combines specialized software and objective data to help law enforcement and civic leadership create safer and healthier neighborhoods FREMONT, Calif., April 10, 2023 (GLOBE NEWSWIRE) — ShotSpotter, Inc. (Nasdaq: SSTI), a leading public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership, today announced a rebranding and name change to SoundThinking™. The new name reflects the company’s focus on public safety through industry-leading law enforcement tools and community-focused solutions for non-law enforcement entities to utilize for a holistic approach to violence prevention, social services and economic assistance. As part of its corporate rebrand, SoundThinking is proud to introduce its...

In IND-enabling studies, HSB-1216 remained tightly bound within the Quatramer™ until reaching its tumor target, consistent with earlier pre-clinical studies demonstrating reduction of tumor growth BRIDGEWATER, N.J., April 10, 2023 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing a portfolio of therapeutic candidates targeting drug resistant and devastating cancers, announced pharmacokinetic (PK) data of HSB-1216 supportive of its development strategy and pre-clinical data. These data suggest Quatramer protects HSB-1216 from metabolic degradation until its release at the tumor site and is consistent with the promising efficacy data demonstrating effective reduction of tumor growth in pre-clinical studies. The preliminary...